Tidsskrift for den Norske Laegeforening, ISSN 0029-2001, 10/2001, Volume 121, Issue 26, pp. 3066 - 3071
Journal Article
European Journal of Cancer, ISSN 0959-8049, 1998, Volume 34, Issue 9, pp. 1368 - 1374
Journal Article
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, ISSN 0029-2001, 04/2003, Volume 123, Issue 7, p. 941
Bronchopulmonary Dysplasia - drug therapy | Antiviral Agents - therapeutic use | Humans | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Infant | Infant, Premature, Diseases - drug therapy | Infant, Premature, Diseases - virology | Bronchopulmonary Dysplasia - complications | Antibodies, Monoclonal, Humanized | Palivizumab | Respiratory Syncytial Virus Infections - drug therapy | Bronchopulmonary Dysplasia - virology | Cost-Benefit Analysis | Adolescent | Respiratory Syncytial Virus Infections - prevention & control | Antibodies, Monoclonal - economics | Child | Infant, Newborn | Practice Guidelines as Topic
Journal Article
Clinical & Experimental Immunology, ISSN 0009-9104, 07/2019, Volume 197, Issue 1, pp. 74 - 82
Summary New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic...
melanoma | anti‐CTLA‐4 | endostatin | immunotherapy | Gal3BP | anti-CTLA-4 | SURVIVAL | CYT-MAA | RECEIVED IPILIMUMAB | IMMUNOLOGY | CANCER | 90K MAC-2 BP | IMMUNE CHECKPOINT BLOCKADE | EXPRESSION | CORRELATE | T-CELLS | SERUM ENDOSTATIN LEVELS | C-reactive protein | Ipilimumab | Immunotherapy | Melanoma | Metastasis | Drug therapy | Biological markers | Protein binding | Endostatin | Antibodies | Cytotoxicity | Activation | Lymphocytes T | Macrophages | Metastases | Skin cancer | Osteoprotegerin | Proteins | Confidence intervals | Cell activation | Biomedical materials | Lymphocytes | Extracellular matrix | Biocompatibility | Antigens | Organs | Lactate dehydrogenase | Inflammation | L-Lactate dehydrogenase | Monocytes | Side effects | Medical prognosis | Fibrosis | Biomarkers | Lactic acid | VDP | Basic medical, dental and veterinary science disciplines: 710 | Medisinske Fag: 700 | Medical disciplines: 700 | Basale medisinske, odontologiske og veterinærmedisinske fag: 710 | Original
melanoma | anti‐CTLA‐4 | endostatin | immunotherapy | Gal3BP | anti-CTLA-4 | SURVIVAL | CYT-MAA | RECEIVED IPILIMUMAB | IMMUNOLOGY | CANCER | 90K MAC-2 BP | IMMUNE CHECKPOINT BLOCKADE | EXPRESSION | CORRELATE | T-CELLS | SERUM ENDOSTATIN LEVELS | C-reactive protein | Ipilimumab | Immunotherapy | Melanoma | Metastasis | Drug therapy | Biological markers | Protein binding | Endostatin | Antibodies | Cytotoxicity | Activation | Lymphocytes T | Macrophages | Metastases | Skin cancer | Osteoprotegerin | Proteins | Confidence intervals | Cell activation | Biomedical materials | Lymphocytes | Extracellular matrix | Biocompatibility | Antigens | Organs | Lactate dehydrogenase | Inflammation | L-Lactate dehydrogenase | Monocytes | Side effects | Medical prognosis | Fibrosis | Biomarkers | Lactic acid | VDP | Basic medical, dental and veterinary science disciplines: 710 | Medisinske Fag: 700 | Medical disciplines: 700 | Basale medisinske, odontologiske og veterinærmedisinske fag: 710 | Original
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 11/2011, Volume 9, Issue 1, pp. 204 - 204
Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in...
Tumor biomarker | Cytotoxic t-lymphocyte antigen-4 | Tumor-infiltrating lymphocytes | Ipilimumab | Melanoma | Indoleamine 2,3-dioxygenase | Foxp3 | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | SOLID TUMORS | INFILTRATING LYMPHOCYTES | Cytotoxic T-lymphocyte antigen-4 | melanoma | PERIPHERAL-BLOOD | OVARIAN-CARCINOMA | PROGNOSTIC-FACTOR | THERAPY | ipilimumab | REGULATORY T-CELLS | tumor-infiltrating lymphocytes | indoleamine 2,3-dioxygenase | FoxP3 | tumor biomarker | ABSOLUTE LYMPHOCYTE COUNT | Immunohistochemistry | Prospective Studies | Skin Neoplasms - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents - adverse effects | Melanoma - genetics | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Skin Neoplasms - pathology | Tumor Microenvironment - drug effects | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | RNA, Messenger - genetics | Treatment Outcome | Melanoma - pathology | Polymorphism, Genetic | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasm Staging | Usage | Messenger RNA | Physiological aspects | Genetic aspects | Research | Biological markers | Gene expression | Studies | Clinical trials | Medical research | Cancer
Tumor biomarker | Cytotoxic t-lymphocyte antigen-4 | Tumor-infiltrating lymphocytes | Ipilimumab | Melanoma | Indoleamine 2,3-dioxygenase | Foxp3 | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | SOLID TUMORS | INFILTRATING LYMPHOCYTES | Cytotoxic T-lymphocyte antigen-4 | melanoma | PERIPHERAL-BLOOD | OVARIAN-CARCINOMA | PROGNOSTIC-FACTOR | THERAPY | ipilimumab | REGULATORY T-CELLS | tumor-infiltrating lymphocytes | indoleamine 2,3-dioxygenase | FoxP3 | tumor biomarker | ABSOLUTE LYMPHOCYTE COUNT | Immunohistochemistry | Prospective Studies | Skin Neoplasms - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents - adverse effects | Melanoma - genetics | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Skin Neoplasms - pathology | Tumor Microenvironment - drug effects | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | RNA, Messenger - genetics | Treatment Outcome | Melanoma - pathology | Polymorphism, Genetic | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasm Staging | Usage | Messenger RNA | Physiological aspects | Genetic aspects | Research | Biological markers | Gene expression | Studies | Clinical trials | Medical research | Cancer
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2017, Volume 28, Issue suppl_5
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, Issue 3, pp. S336 - S337
It is well documented that IFN-alfa-2b and PEGIFN-alfa-2b significantly prolong RFS, but has no significant effect on overall survival. Currently, IFNalfa- 2b...
Hematology, Oncology and Palliative Medicine | ONCOLOGY | Meta-Analysis as Topic | Skin Neoplasms - therapy | Chemotherapy, Adjuvant - methods | Combined Modality Therapy - trends | Humans | Combined Modality Therapy - methods | Melanoma - therapy | Adjuvants, Immunologic - therapeutic use | Antimitotic agents | Care and treatment | Antineoplastic agents | Melanoma | Cancer
Hematology, Oncology and Palliative Medicine | ONCOLOGY | Meta-Analysis as Topic | Skin Neoplasms - therapy | Chemotherapy, Adjuvant - methods | Combined Modality Therapy - trends | Humans | Combined Modality Therapy - methods | Melanoma - therapy | Adjuvants, Immunologic - therapeutic use | Antimitotic agents | Care and treatment | Antineoplastic agents | Melanoma | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 2, pp. 144 - 152
Summary Background Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall...
Hematology, Oncology and Palliative Medicine | ONCOLOGY | CUTANEOUS MELANOMA | Humans | Middle Aged | Risk Factors | Interferon-alpha - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Recombinant Proteins | Dose-Response Relationship, Drug | Disease-Free Survival | Time Factors | Chemotherapy, Adjuvant - methods | Melanoma - drug therapy | Adolescent | Adult | Female | Aged | Care and treatment | Biological response modifiers | Viral antigens | Melanoma | Interferon alpha | Index Medicus | Drug | drug therapy | methods | Antineoplastic Agents | Chemotherapy | Adjuvant | Dose-Response Relationship | Interferon Alfa-2b | Cancer and Oncology | therapeutic use | Cancer och onkologi
Hematology, Oncology and Palliative Medicine | ONCOLOGY | CUTANEOUS MELANOMA | Humans | Middle Aged | Risk Factors | Interferon-alpha - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Recombinant Proteins | Dose-Response Relationship, Drug | Disease-Free Survival | Time Factors | Chemotherapy, Adjuvant - methods | Melanoma - drug therapy | Adolescent | Adult | Female | Aged | Care and treatment | Biological response modifiers | Viral antigens | Melanoma | Interferon alpha | Index Medicus | Drug | drug therapy | methods | Antineoplastic Agents | Chemotherapy | Adjuvant | Dose-Response Relationship | Interferon Alfa-2b | Cancer and Oncology | therapeutic use | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 10, pp. 1191 - 1196
Purpose There is evidence from nonrandomized studies that a proportion of ipilimumab-treated patients with advanced melanoma experience long-term survival. To...
ONCOLOGY | METASTATIC MELANOMA | CANCER-IMMUNOTHERAPY | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Drug Administration Schedule | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Survival Rate | Treatment Outcome | Diarrhea - chemically induced | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Exanthema - chemically induced | Melanoma - drug therapy | Survival Analysis | Female | Aged | Vitiligo - chemically induced | Pruritus - chemically induced | Melanoma - mortality | Original Reports
ONCOLOGY | METASTATIC MELANOMA | CANCER-IMMUNOTHERAPY | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Drug Administration Schedule | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Survival Rate | Treatment Outcome | Diarrhea - chemically induced | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Exanthema - chemically induced | Melanoma - drug therapy | Survival Analysis | Female | Aged | Vitiligo - chemically induced | Pruritus - chemically induced | Melanoma - mortality | Original Reports
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 9/2013, Volume 62, Issue 9, pp. 1499 - 1509
The growth and recurrence of several cancers appear to be driven by a population of cancer stem cells (CSCs). Glioblastoma, the most common primary brain...
Dendritic cell | Immunology | Tumorsphere | Autologous cell culture | Medicine & Public Health | Immunotherapy | Brain cancer stem cell | Glioblastoma | Oncology | Cancer Research | PROGENITOR CELLS | NERVOUS-SYSTEM | INDUCTION | IMMUNOLOGY | TUMORS | TRIAL | IN-VITRO | ONCOLOGY | ADULT HUMAN BRAIN | MALIGNANT GLIOMAS | EXPRESSION | T-LYMPHOCYTE RESPONSES | Immunotherapy, Adoptive - methods | Cancer Vaccines - administration & dosage | Dendritic Cells - immunology | Humans | Middle Aged | RNA, Messenger - genetics | Brain Neoplasms - pathology | Dendritic Cells - pathology | Neoplastic Stem Cells - immunology | Male | Combined Modality Therapy | Telomerase - immunology | Glioblastoma - therapy | Cancer Vaccines - immunology | Disease-Free Survival | Brain Neoplasms - immunology | Telomerase - genetics | Transfection | Glioblastoma - immunology | Glioblastoma - pathology | Brain Neoplasms - therapy | Neoplastic Stem Cells - pathology | Female | Care and treatment | Messenger RNA | Dendritic cells | Vaccination | Stem cells | Health aspects | Cancer | Autografts | Original
Dendritic cell | Immunology | Tumorsphere | Autologous cell culture | Medicine & Public Health | Immunotherapy | Brain cancer stem cell | Glioblastoma | Oncology | Cancer Research | PROGENITOR CELLS | NERVOUS-SYSTEM | INDUCTION | IMMUNOLOGY | TUMORS | TRIAL | IN-VITRO | ONCOLOGY | ADULT HUMAN BRAIN | MALIGNANT GLIOMAS | EXPRESSION | T-LYMPHOCYTE RESPONSES | Immunotherapy, Adoptive - methods | Cancer Vaccines - administration & dosage | Dendritic Cells - immunology | Humans | Middle Aged | RNA, Messenger - genetics | Brain Neoplasms - pathology | Dendritic Cells - pathology | Neoplastic Stem Cells - immunology | Male | Combined Modality Therapy | Telomerase - immunology | Glioblastoma - therapy | Cancer Vaccines - immunology | Disease-Free Survival | Brain Neoplasms - immunology | Telomerase - genetics | Transfection | Glioblastoma - immunology | Glioblastoma - pathology | Brain Neoplasms - therapy | Neoplastic Stem Cells - pathology | Female | Care and treatment | Messenger RNA | Dendritic cells | Vaccination | Stem cells | Health aspects | Cancer | Autografts | Original
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 2011, Volume 9, Issue 1, pp. 214 - 214
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in...
MEDICINE, RESEARCH & EXPERIMENTAL | METASTATIC MELANOMA | IMMUNE-RESPONSE | ADVERSE EVENT | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | T-CELL RESPONSES | CLINICAL-TRIAL | TRANSLATIONAL RESEARCH | VACCINE-CONSORTIUM | PROSTATE-CANCER | BLOCKADE | Neoplasms - therapy | International Cooperation | Humans | Immunotherapy | Translational Medical Research | Care and treatment | Research | Health aspects | Cancer | Science | Medical research | Hospitals | Ratings & rankings | Colleges & universities | Life Sciences | Human health and pathology
MEDICINE, RESEARCH & EXPERIMENTAL | METASTATIC MELANOMA | IMMUNE-RESPONSE | ADVERSE EVENT | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | T-CELL RESPONSES | CLINICAL-TRIAL | TRANSLATIONAL RESEARCH | VACCINE-CONSORTIUM | PROSTATE-CANCER | BLOCKADE | Neoplasms - therapy | International Cooperation | Humans | Immunotherapy | Translational Medical Research | Care and treatment | Research | Health aspects | Cancer | Science | Medical research | Hospitals | Ratings & rankings | Colleges & universities | Life Sciences | Human health and pathology
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2014, Volume 134, Issue 1, pp. 102 - 113
Cancer cells escape T‐cell‐mediated destruction by losing human leukocyte antigen (HLA) class I expression via various mechanisms, including loss of...
tumor HLA class I loss | immune escape | beta2‐microglobulin mutation | metastatic melanoma | beta2-microglobulin mutation | GENE-MUTATIONS | ANTIGEN PRESENTATION | MECHANISMS | PHENOTYPES | IDENTIFICATION | BETA-MICROGLOBULIN | ONCOLOGY | IMMUNOTHERAPY | REJECTION | RESISTANCE | CLASS-I EXPRESSION | Immunohistochemistry | Tumor Escape - genetics | Humans | Histocompatibility Antigens Class I - immunology | Histocompatibility Antigens Class I - genetics | Melanoma - pathology | beta 2-Microglobulin - immunology | Loss of Heterozygosity | Reverse Transcriptase Polymerase Chain Reaction | Neoplasm Metastasis | Flow Cytometry | Melanoma - genetics | Melanoma - immunology | Neoplasm Invasiveness - pathology | Cell Line, Tumor | Aged | Histocompatibility Antigens Class I - biosynthesis | Mutation | Neoplasm Invasiveness - genetics | beta 2-Microglobulin - genetics | Tumor Escape - immunology | Histocompatibility antigens | Analysis | Immunotherapy | Melanoma | HLA histocompatibility antigens | Development and progression | Metastasis | T cells | Chromosomes | Cancer | Genes | Biomarkers | Tumors | Biopsy
tumor HLA class I loss | immune escape | beta2‐microglobulin mutation | metastatic melanoma | beta2-microglobulin mutation | GENE-MUTATIONS | ANTIGEN PRESENTATION | MECHANISMS | PHENOTYPES | IDENTIFICATION | BETA-MICROGLOBULIN | ONCOLOGY | IMMUNOTHERAPY | REJECTION | RESISTANCE | CLASS-I EXPRESSION | Immunohistochemistry | Tumor Escape - genetics | Humans | Histocompatibility Antigens Class I - immunology | Histocompatibility Antigens Class I - genetics | Melanoma - pathology | beta 2-Microglobulin - immunology | Loss of Heterozygosity | Reverse Transcriptase Polymerase Chain Reaction | Neoplasm Metastasis | Flow Cytometry | Melanoma - genetics | Melanoma - immunology | Neoplasm Invasiveness - pathology | Cell Line, Tumor | Aged | Histocompatibility Antigens Class I - biosynthesis | Mutation | Neoplasm Invasiveness - genetics | beta 2-Microglobulin - genetics | Tumor Escape - immunology | Histocompatibility antigens | Analysis | Immunotherapy | Melanoma | HLA histocompatibility antigens | Development and progression | Metastasis | T cells | Chromosomes | Cancer | Genes | Biomarkers | Tumors | Biopsy
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, pp. 18033 - 18033
Disease caused by antibiotic resistant pathogens is becoming a serious problem, both in human and veterinary medicine. The inhibition of quorum sensing,...
ANTIBIOTICS | IMPACT | MULTIDISCIPLINARY SCIENCES | INHIBITORS | VIBRIO-HARVEYI | VIRULENCE | FURANONE | Virulence - drug effects | Artemia - microbiology | Quorum Sensing - drug effects | Sulfhydryl Compounds - pharmacology | Bacteria - drug effects | Artemia - drug effects | Animals | Larva | Anti-Bacterial Agents - chemistry | Phenols - chemistry | Sulfhydryl Compounds - chemistry | Anti-Bacterial Agents - pharmacology | Phenols - pharmacology | Chemical communication | Cell interactions | Toxicity | Antibiotic resistance | Index Medicus
ANTIBIOTICS | IMPACT | MULTIDISCIPLINARY SCIENCES | INHIBITORS | VIBRIO-HARVEYI | VIRULENCE | FURANONE | Virulence - drug effects | Artemia - microbiology | Quorum Sensing - drug effects | Sulfhydryl Compounds - pharmacology | Bacteria - drug effects | Artemia - drug effects | Animals | Larva | Anti-Bacterial Agents - chemistry | Phenols - chemistry | Sulfhydryl Compounds - chemistry | Anti-Bacterial Agents - pharmacology | Phenols - pharmacology | Chemical communication | Cell interactions | Toxicity | Antibiotic resistance | Index Medicus
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 6/2011, Volume 60, Issue 6, pp. 809 - 818
Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT...
Immunology | Medicine & Public Health | Epitope identification | Pancreas cancer | Cancer Research | Oncology | Telomerase (hTERT) | Dendritic cell vaccination | CD8(+) | PHASE-I/II | INDUCTION | IMMUNOLOGY | IDENTIFICATION | TUMOR-ANTIGEN | MELANOMA | ONCOLOGY | GENERATION | TELOMERASE PEPTIDE VACCINATION | T-CELLS | CROSS-PRESENTATION | Cell Growth Processes - immunology | RNA, Messenger - immunology | Dendritic Cells - immunology | Humans | Middle Aged | Telomerase - immunology | Carcinoma, Pancreatic Ductal - genetics | Cancer Vaccines - genetics | Epitopes - immunology | Cancer Vaccines - therapeutic use | Telomerase - genetics | Transfection | Female | Carcinoma, Pancreatic Ductal - immunology | T-Lymphocytes, Cytotoxic - immunology | Pancreatic Neoplasms - pathology | RNA, Messenger - genetics | Pancreatic Neoplasms - genetics | Carcinoma, Pancreatic Ductal - therapy | Epitopes - genetics | Carcinoma, Pancreatic Ductal - pathology | Cancer Vaccines - immunology | T-Lymphocytes, Cytotoxic - metabolism | Pancreatic Neoplasms - immunology | Cell Line, Tumor | Pancreatic Neoplasms - therapy | Care and treatment | Peptides | Dendritic cells | Vaccination | Oncology, Experimental | Research | T cells | Pets | Chemotherapy | Messenger RNA | Analysis | Pancreatic cancer | Telomerase | Antigenic determinants | Cancer | Adenocarcinoma | Immune response | Cytotoxicity | Lymphocytes T | mRNA | Epitopes | Vaccines | Radicals | Computed tomography | Immunotherapy | Surgery | Remission | gemcitabine | telomerase reverse transcriptase | Neutropenia | Original
Immunology | Medicine & Public Health | Epitope identification | Pancreas cancer | Cancer Research | Oncology | Telomerase (hTERT) | Dendritic cell vaccination | CD8(+) | PHASE-I/II | INDUCTION | IMMUNOLOGY | IDENTIFICATION | TUMOR-ANTIGEN | MELANOMA | ONCOLOGY | GENERATION | TELOMERASE PEPTIDE VACCINATION | T-CELLS | CROSS-PRESENTATION | Cell Growth Processes - immunology | RNA, Messenger - immunology | Dendritic Cells - immunology | Humans | Middle Aged | Telomerase - immunology | Carcinoma, Pancreatic Ductal - genetics | Cancer Vaccines - genetics | Epitopes - immunology | Cancer Vaccines - therapeutic use | Telomerase - genetics | Transfection | Female | Carcinoma, Pancreatic Ductal - immunology | T-Lymphocytes, Cytotoxic - immunology | Pancreatic Neoplasms - pathology | RNA, Messenger - genetics | Pancreatic Neoplasms - genetics | Carcinoma, Pancreatic Ductal - therapy | Epitopes - genetics | Carcinoma, Pancreatic Ductal - pathology | Cancer Vaccines - immunology | T-Lymphocytes, Cytotoxic - metabolism | Pancreatic Neoplasms - immunology | Cell Line, Tumor | Pancreatic Neoplasms - therapy | Care and treatment | Peptides | Dendritic cells | Vaccination | Oncology, Experimental | Research | T cells | Pets | Chemotherapy | Messenger RNA | Analysis | Pancreatic cancer | Telomerase | Antigenic determinants | Cancer | Adenocarcinoma | Immune response | Cytotoxicity | Lymphocytes T | mRNA | Epitopes | Vaccines | Radicals | Computed tomography | Immunotherapy | Surgery | Remission | gemcitabine | telomerase reverse transcriptase | Neutropenia | Original
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 30, pp. 3831 - 3837
Purpose The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG...
CONTROLLED CLINICAL-TRIAL | HIGH-RISK MELANOMA | ANTIBODIES | SURVIVAL | INTERFERON-ALPHA | KEYHOLE LIMPET HEMOCYANIN | METAANALYSIS | PROGNOSTIC-FACTORS | ONCOLOGY | GM2 GANGLIOSIDE | MALIGNANT-MELANOMA | Lymph Nodes - pathology | Lymph Nodes - surgery | Humans | Middle Aged | Male | Cancer Vaccines - therapeutic use | Skin Neoplasms - prevention & control | Melanoma - prevention & control | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Saponins - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Skin Neoplasms - pathology | Hemocyanins - therapeutic use | Kaplan-Meier Estimate | Lymphatic Metastasis | Melanoma - pathology | Disease-Free Survival | Watchful Waiting | Aged | Melanoma - surgery | Neoplasm Staging | G(M2) Ganglioside - therapeutic use | Melanoma - mortality | Index Medicus
CONTROLLED CLINICAL-TRIAL | HIGH-RISK MELANOMA | ANTIBODIES | SURVIVAL | INTERFERON-ALPHA | KEYHOLE LIMPET HEMOCYANIN | METAANALYSIS | PROGNOSTIC-FACTORS | ONCOLOGY | GM2 GANGLIOSIDE | MALIGNANT-MELANOMA | Lymph Nodes - pathology | Lymph Nodes - surgery | Humans | Middle Aged | Male | Cancer Vaccines - therapeutic use | Skin Neoplasms - prevention & control | Melanoma - prevention & control | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Saponins - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Skin Neoplasms - pathology | Hemocyanins - therapeutic use | Kaplan-Meier Estimate | Lymphatic Metastasis | Melanoma - pathology | Disease-Free Survival | Watchful Waiting | Aged | Melanoma - surgery | Neoplasm Staging | G(M2) Ganglioside - therapeutic use | Melanoma - mortality | Index Medicus
Journal Article